Hu Xiao-Qing, Chen Wei-Li, Ma Hai-Guang, Jiang Ke
Department of Surgical Oncology, Wenzhou Central Hospital, Zhejiang, China.
Department of Breast Surgery, Yue Yang Hospital of Traditional Chinese & Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Oncotarget. 2017 Apr 7;8(34):56364-56374. doi: 10.18632/oncotarget.16913. eCollection 2017 Aug 22.
In this study we sought to investigate the prevalence and prognostic value of androgen receptor (AR) status in operable triple-negative breast cancer (TNBC) patients. We collected the clinical data of 360 patients with TNBC, and found a positivity AR expression of 31.4% with a cut-off value of 10%. Tumors expressing the negative CK5/6 (P=0.013) and low Ki-67 (P=0.007) are more likely to have positive AR. In multivariate survival analysis, AR expression is correlated with increased DFS (HR=0.467, 95%CI 0.271-0.805; P=0.006) and OS (HR=0.488, 95%CI 0.267-0.894, P=0.020) independently. In addition, patients with AR+ tumors are more likely to have favorable outcome in patients with young, pre-menopausal, large tumor size, more node involvement (4+), high stage, high grade, vascular invasion+, P53+, CK5/6-, and higher Ki-67. Our study has indicated that the absence of AR might help to identify patients with relatively higher risk of disease relapse and death, and further clinical studies of anti-androgen agents are warranted to enrich the therapeutic strategy options for AR+ TNBCs.
在本研究中，我们旨在调查雄激素受体（AR）状态在可手术三阴性乳腺癌（TNBC）患者中的患病率及预后价值。我们收集了360例TNBC患者的临床数据，发现AR表达阳性率为31.4%，临界值为10%。表达阴性CK5/6（P = 0.013）和低Ki-67（P = 0.007）的肿瘤更有可能出现AR阳性。在多因素生存分析中，AR表达与DFS增加（HR = 0.467，95%CI 0.271 - 0.805；P = 0.006）和OS增加（HR = 0.488，95%CI 0.267 - 0.894，P = 0.020）独立相关。此外，AR阳性肿瘤患者在年龄较小、绝经前、肿瘤体积大、更多淋巴结受累（4个及以上）、高分期、高分级、血管侵犯阳性、P53阳性、CK5/6阴性和Ki-67较高的患者中更有可能获得良好预后。我们的研究表明，AR缺失可能有助于识别疾病复发和死亡风险相对较高的患者，有必要进一步开展抗雄激素药物的临床研究，以丰富AR阳性TNBC的治疗策略选择。
